HAEMONETICS CORP (HAE) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for HAEMONETICS CORP (HAE): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 50/100 — a percentile rank of HAEMONETICS CORP’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $4.7B |
| P / E | 49.3× |
| P / S | 3.5× |
| EV / EBITDA | 16.1× |
| Gross margin | 59.0% |
| Operating margin | 11.9% |
| Net margin | 7.1% |
| Return on equity | 11.5% |
| ROIC | 6.6% |
| Revenue growth | 0.4% |
| Debt / equity | 1.4× |
| Dividend yield | 0.0% |
Is HAEMONETICS CORP overvalued? P/E looks overvalued vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from HAEMONETICS CORP’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact